Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $3.36
Previous CloseN/A
Volume101.31K
Average Volume (3M)290.63K
Market Cap
$82.38M
Enterprise Value-$43.00M
Total Cash (Recent Filing)$143.37M
Total Debt (Recent Filing)$29.88M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Nov 17, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding60,573,425
10 Day Avg. Volume242,701
30 Day Avg. Volume290,632
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.52
Enterprise Value/Revenue-241.59
Enterprise Value/Gross Profit43.00K
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$8.50Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Cash ReservesABOS finished 2024 with $231.5M in cash and cash equivalents, sufficient to fund operations into 1H27.
Product DifferentiationThe deal with JCR’s technology may improve Acumen’s antibody delivery, potentially bolstering efficacy while adding another source of product differentiation.
Trial EnrollmentAcumen Pharmaceuticals has completed enrollment for the ALTITUDE AD trial, showing strong interest in their differentiated anti-Abeta immunotherapy.
Bears Say
Financial ConcernsAcumen shares are under pressure largely due to concerns about the financial outlay, despite few risks being seen.
Price Target ReductionThe reevaluation of operational expense assumptions has led to a reduction in the price target from $15 to $11.
SubQ FormulationThe subQ formulation of sabirnetug, although showing a decent safety profile, has a very high proportion of mild injection site reactions at around 62.5%.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $0.85 and its highest was $3.36 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $82.38M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Nov 17, 2025 which is in 74 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.489 by -$0.191.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.57.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,573,425 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.489. Following the earnings report the stock price went down -11.268%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (525.00% Upside)
$8.50 (525.00% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.36%
12-Months-Change
Fundamentals
Return on Equity
-75.71%
Trailing 12-Months
Asset Growth
-40.50%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of neurodegenerative diseases, with an emphasis on Alzheimer's disease. The company's lead product candidate is ACU193, a monoclonal antibody that selectively targets toxic amyloid-beta oligomers, which are believed to play a key role in the pathogenesis of Alzheimer's disease. Acumen Pharmaceuticals is engaged in advancing its clinical trials and research to address unmet medical needs in the neurodegenerative disease sector.
ABOS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical studies and strategic partnerships, particularly with JCR Pharmaceuticals, which is expected to enhance their Alzheimer's treatment portfolio. Financially, the company maintains a strong cash position, although increased R&D expenses and operational losses were noted. The overall sentiment around Alzheimer's therapies is positive, with advancements in diagnostics and treatments. Despite financial challenges, the strategic and clinical advancements suggest a positive outlook.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$8.50
▲(525.00% Upside)
Technical Analysis
Medicinova
―
Assembly Biosciences
―
Rani Therapeutics Holdings
―
Invivyd
―
Genenta Science SpA Sponsored ADR
―
Ownership Overview
27.47% Insiders
10.69% Mutual Funds
40.04% Other Institutional Investors
19.22% Public Companies and
Individual Investors